Sold as Vancomycin. Every FDA application for this active ingredient.
As of Nov 13, 2026, FDA lists 1 application for Vancomycin (sold as Vancomycin), first approved Aug 26, 2021, with 0 new uses approved and 1 published complete response letter.
| Product | Part | Spending, 2024 | Change | Beneficiaries |
|---|---|---|---|---|
| Vancomycin HCl | Part D | $52.3M | -21% | 172,023 |
| Firvanq | Part D | $510K | -56% | 1,862 |
| Vancocin HCl | Part D | $418K | -21% | 25 |
| Vancomycin HCL (J3371) | Part B | $116K | +24430% | 5,227 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Aug 26, 2021 | VancomycinNDA 213895 ยท New formulation or manufacturer | Hikma | 0 | Discontinued |
| Letter | Product | Now |
|---|---|---|
| Mar 20, 2020 | Vancomycin | Approved |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number. Drugs@FDA
